-
公开(公告)号：US20230287134A1
公开(公告)日：2023-09-14
申请号：US18153181
申请日：2023-01-11
申请人： UCB BIOPHARMA SRL
CPC分类号： C07K16/289 , C07K16/18 , C07K16/2803 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/24 , C07K2317/76 , C07K2317/90 , C07K2317/35 , C07K2317/64 , C07K2317/624
摘要： The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
-
公开(公告)号：US20230151108A1
公开(公告)日：2023-05-18
申请号：US17929026
申请日：2020-02-13
申请人： UCB BIOPHARMA SRL
IPC分类号： C07K16/28 , C07K14/765 , A61P35/00
CPC分类号： C07K16/2896 , C07K16/2878 , C07K14/765 , A61P35/00 , A61K2039/505
摘要： The present invention relates to multispecific antibodies against a novel targets' combination of CD137 and CD9, and their use in the treatment of cancer and infectious diseases.
-
公开(公告)号：US20230125234A1
公开(公告)日：2023-04-27
申请号：US17929032
申请日：2020-02-13
申请人： UCB BIOPHARMA SRL
摘要： The present disclosure relates to a bispecific anti CD44/anti CTLA4 antibody. The antibody construct has defined CDRs and variable chains sequences. The bispecific antibodies has improved activity on CDS and CD4 T cells compared to known antibodies.
-
公开(公告)号：US20230151109A1
公开(公告)日：2023-05-18
申请号：US17929031
申请日：2020-02-13
申请人： UCB BIOPHARMA SRL
CPC分类号： C07K16/2896 , C07K16/2878 , A61P35/00 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/75
摘要： The present invention relates to multispecific antibodies against a novel targets' combination of CD9 and another antigen, and their use in the treatment of cancer and infectious diseases.
-
公开(公告)号：US20230096030A1
公开(公告)日：2023-03-30
申请号：US17929029
申请日：2020-02-13
申请人： UCB BIOPHARMA SRL
IPC分类号： C07K16/28
摘要： The present invention relates to multispecific antibodies against a novel targets' combination of CD7 and CD9, and their use in the treatment of cancer and infectious diseases.
-
公开(公告)号：US20230065921A1
公开(公告)日：2023-03-02
申请号：US17821688
申请日：2022-08-23
申请人： UCB Biopharma SRL
IPC分类号： C07K16/28 , A01K67/027
摘要： The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
公开(公告)号：US20210140972A1
公开(公告)日：2021-05-13
申请号：US17072665
申请日：2020-10-16
申请人： UCB BIOPHARMA SRL
发明人： James Philip O'CONNELL , John Robert PORTER , Alastair LAWSON , Boris KROEPLIEN , Stephen Edward RAPECKI , Timothy John NORMAN , David James MCMILLAN , Graham John WARRELLOW , Daniel Christopher BROOKINGS , Rikki Peter ALEXANDER
IPC分类号： G01N33/68 , C07D401/14 , C07K14/525 , C07D471/00 , C07K14/705 , C07K16/24 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
摘要： The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
-
公开(公告)号：US20210088530A1
公开(公告)日：2021-03-25
申请号：US17013326
申请日：2020-09-04
申请人： UCB BIOPHARMA SRL
发明人： James Philip O'CONNELL , John Robert PORTER , Alastair LAWSON , Boris KROEPLIEN , Stephen Edward RAPECKI , Timothy John NORMAN , Graham John WARRELLOW , Tracy Lynn ARAKAKI , Alex Buntin BURGIN , William Ross PITT , Mark Daniel CALMIANO , David Andreas SCHUBERT , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO
IPC分类号： G01N33/68 , C07D401/14 , C07K14/525 , C07D471/00 , C07K14/705 , C07K16/24 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
摘要： A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
-
公开(公告)号：US20230374148A1
公开(公告)日：2023-11-23
申请号：US18248651
申请日：2021-10-14
申请人： UCB BIOPHARMA SRL
发明人： Stephen Edward RAPECKI , Ralph ADAMS , David Paul HUMPHREYS , Helen Margaret FINNEY , Rosemary Frances BITHELL
CPC分类号： C07K16/289 , C07K16/18 , A61P35/00 , A61P35/02 , C07K2317/31 , C07K2317/52 , C07K2317/24 , C07K2317/73 , C07K2317/72 , C07K2317/55 , C07K2317/92 , C07K2317/35
摘要： The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.
-
公开(公告)号：US20230192900A1
公开(公告)日：2023-06-22
申请号：US17929028
申请日：2020-02-13
申请人： UCB BIOPHARMA SRL
IPC分类号： C07K16/46
CPC分类号： C07K16/468 , C07K2317/31 , C07K2317/24 , C07K2317/94 , C07K2317/565
摘要： The present invention relates to multispecific antibodies against a novel targets' combination of HVEM and CD9, and their use in the treatment of cancer and infectious diseases.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.017 秒)
